Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
Elena Inzoli, Andrea Aroldi, Rocco Piazza, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 8, pp. 1075-1085
Open Access | Times Cited: 21

Showing 21 citing articles:

Pharmacogenomics: current status and future perspectives
Munir Pirmohamed
Nature Reviews Genetics (2023) Vol. 24, Iss. 6, pp. 350-362
Closed Access | Times Cited: 169
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)
Elisabetta Abruzzese, Monica Bocchia, Malgorzata Monika Trawinska, et al.
Cancers (2023) Vol. 15, Iss. 16, pp. 4112-4112
Open Access | Times Cited: 23
Chronic myeloid leukaemia: Biology and therapy
Yun Wang, Zhi-Jian Liang, Robert Peter Gale, et al.
Blood Reviews (2024) Vol. 65, pp. 101196-101196
Closed Access | Times Cited: 8
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells
Paola Pacelli, Adele Santoni, Anna Sicuranza, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 16
Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence
Jyotirmoy Sarker, Ehab Atallah, Kathryn E. Flynn, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-6
Closed Access
Real World Outcomes with Treatment Free Remission in Chronic Myeloid Leukemia-Experience from a Tertiary Care Cancer Centre
Rup Jyoti Sarma, Lakhan Kashyap, Anne Srikanth, et al.
Indian Journal of Hematology and Blood Transfusion (2024) Vol. 40, Iss. 4, pp. 564-572
Closed Access | Times Cited: 3
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I‐BFM Study Group
Herbert Pichler, Petr Sedláček, Roland Meisel, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 268-279
Open Access | Times Cited: 3
BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach
Jenna M. Menger, Ryan S. Sathianathen, Kathleen M. Sakamoto, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 3, pp. 250-257
Closed Access | Times Cited: 2
Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential
Jixian Huang, Jie Xiao, Lifeng He, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 14
Open Access | Times Cited: 2
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
Giovanni Paolo Maria Zambrotta, Franck E. Nicolini, Sarit Assouline, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 11, pp. 1762-1771
Open Access | Times Cited: 4
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, et al.
Annals of Hematology (2024) Vol. 103, Iss. 5, pp. 1561-1568
Open Access | Times Cited: 1
Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation
Mingshan Sun, Shijie Li, Zhenyi Liu, et al.
Leukemia Research (2024) Vol. 142, pp. 107507-107507
Closed Access | Times Cited: 1
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety
Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 8, pp. 969-979
Closed Access | Times Cited: 1
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
Federica Malighetti, Giulia Arosio, Chiara Manfroni, et al.
HemaSphere (2023) Vol. 7, Iss. 3, pp. e852-e852
Open Access | Times Cited: 2
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors
Hong Chen, Yan Wen, Yun Zeng, et al.
Oncology and Therapy (2023) Vol. 12, Iss. 1, pp. 131-145
Open Access | Times Cited: 2
Exploration of treatment‐free remission in CML, based on molecular monitoring
Zhao Zhang, Wuneng Zhou, Xin Zhou, et al.
Cancer Medicine (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
Carlo Gambacorti‐Passerini, Franck E. Nicolini, Richard A. Larson, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 8
Open Access | Times Cited: 3
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
Fadi G. Haddad, Nicholas J. Short
American Journal of Hematology (2023) Vol. 98, Iss. 11, pp. 1670-1672
Open Access | Times Cited: 1
Autophagy as a Limiting Factor to the Effectiveness of Tyrosine Kinase Inhibitors in Blood Cancers
Keli Lima, Manuela Albuquerque de Melo, Brunno Gilberto Santos de Macedo, et al.
Springer eBooks (2024)
Closed Access
Advances in the Treatment of Chronic Myeloid Leukemia
Romeo-Gabriel Mihăilă
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 1, pp. 1-17
Closed Access
Page 1

Scroll to top